Targeting the epigenetic addiction of Merkel cell carcinoma
| Autor: | Cédric Blanpain, Federico Mauri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Medicine (General) Skin Neoplasms animal structures media_common.quotation_subject medicine.medical_treatment QH426-470 Chromatin Epigenetics Genomics & Functional Genomics Epigenesis Genetic 03 medical and health sciences 0302 clinical medicine R5-920 medicine Genetics Humans News & Views Epigenetics media_common Cancer Skin biology integumentary system Merkel cell carcinoma business.industry Addiction food and beverages Immunotherapy Sciences bio-médicales et agricoles medicine.disease Molecular medicine Carcinoma Merkel Cell 030104 developmental biology medicine.anatomical_structure Histone biology.protein Cancer research Molecular Medicine Demethylase business Merkel cell 030217 neurology & neurosurgery |
| Zdroj: | EMBO molecular medicine EMBO Molecular Medicine, Vol 12, Iss 11, Pp n/a-n/a (2020) EMBO Molecular Medicine |
| Popis: | Merkel cell carcinoma (MCC) is a rare but very aggressive neuroendocrine cancer of the skin, with very limited therapeutic options. Although immunotherapy is effective in some cases, there is an unmet need for new therapeutic approaches in MCCs. In this issue of EMBO Molecular Medicine, Leiendecker et al identify a selective vulnerability of MCC for inhibitors of the lysine‐specific histone demethylase 1A (LSD1). LSD1 inhibitors promote differentiation of tumor cells toward normal Merkel cell fate, impairing tumor cell growth in vivo, and opening new avenues for the treatment of patients with MCC. F. Mauri and C. Blanpain discuss the identification of a selective vulnerability of Merkel cell carcinomas for LSD1, which could be used for establishing new therapeutic strategies, as reported by A. Obenauf and colleagues in this issue of EMBO Mol. Med. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|